BridgeMD
Angiotensin II for more effective radioembolization in liver cancer: the RADIANT study
EU CTIS ID: 2025-521870-33-00
What this study is testing
The primary objective is to assess the difference in tumor-to-non-tumor ratio (TNR) after the injection of 90Y glass microspheres with AT-II infusion compared to the TNR after 99mTc-MAA injection without AT-II infusion (i.e., the TNR improvement factor).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients diagnosed with primary or metastatic liver tumors (any histological type)
- Liver tumors with a tumor diameter ≥ 2 cm
- Age ≥ 18 years
- Written informed consent
- A clinical indication for radioembolization
- Competent and able to provide own informed consent (no legally designated representative)
You likely can't join if
- Any serious comorbidity preventing the safe administration of AT-II. This includes uncontrolled hypertension or treatment with ≥3 antihypertensive drugs, arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months
- Known hypersensitivity to the active substance in Giapreza: angiotensin II
- Known hypersensitivty to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid
- Known severe allergy for intravenous contrast fluids
- Participation to another investigational study which may compromise any endpoint of the study
- Any other significant comorbidity or medical condition that may compromise the safety of radioembolization
See the full eligibility criteria
- Patients diagnosed with primary or metastatic liver tumors (any histological type)
- Liver tumors with a tumor diameter ≥ 2 cm
- Age ≥ 18 years
- Written informed consent
- A clinical indication for radioembolization
- Competent and able to provide own informed consent (no legally designated representative)
- Any serious comorbidity preventing the safe administration of AT-II. This includes uncontrolled hypertension or treatment with ≥3 antihypertensive drugs, arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months
- Known hypersensitivity to the active substance in Giapreza: angiotensin II
- Known hypersensitivty to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid
- Known severe allergy for intravenous contrast fluids
- Participation to another investigational study which may compromise any endpoint of the study
- Any other significant comorbidity or medical condition that may compromise the safety of radioembolization
- Any serious and/or chronic liver disease preventing the safe administration of radioembolization
- Uncorrectable extrahepatic deposition of scout dose activity; activity in the falciform ligament, portal lymph nodes and gallbladder is accepted
- Pregnancy or breastfeeding
- Body weight over 150 kg (because of maximum table load)
- Current use of angiotensin-converting enzyme inhibitors
- Current use of angiotensin II receptor blockers (ARBs)
- Known hypercoagulable state (i.e., thrombophilia)
- History of severe peripheral vascular disease
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.